This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The prognosis for multiple sclerosis is very variable.

After typically 10 to 20 years, a progressive clinical course develops in many of the persons affected, eventually leading to impaired mobility and cognition; approximately 15% of patients have a progressive course from onset (1).

  • most patients (85%–90%) have a relapsing course from onset that is characterized by relapses and remissions of neurological symptoms associated with areas of CNS inflammation
    • over the course of two decades more than half of untreated patients transition to a phase of gradual worsening independent of acute attacks (secondary progressive MS)
  • progressive forms of MS can be present as the initial disease course (primary progressive MS) in approximately 10%–15% of patients (2)

Prognosis is dependent on the (3):

  • number of attacks - a high frequency of relapses in the first few years is a bad prognostic sign; the average relapse rate in first few years is approximately one per year
  • type of attack:
    • primary symptoms of visual loss are associated with a better outlook
    • primary motor attacks, ataxia, or bulbar problems are associated with a poor prognosis

Clinical factors that have been associated with poorer prognosis include (3,4):

  • MS in males
  • older at age of onset of MS
  • if MS has a multifocal presentation
  • involvement of pyramidal and cerebellar systems.
  • partial recovery from relapses.
  • high frequency of relapses in the first few years
  • higher lesion burden on magnetic resonance imaging.

Life expectancy:

  • average life expectancy for people with MS is around 5 to 10 years lower than average, and this gap appears to be getting smaller all the time (5)

Reference:

  • Reich DS et al. Multiple Sclerosis. N Engl J Med 2018;378:169-80.
  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.European Journal of Neurology 2018, 25: 215–237
  • Confavreux et al. Relapses and progression of multiple sclerosis. NEJM 2000;343:1430-1438.
  • NHS CKS. Multiple Sclerosis (Accessed 20/11/2020)
  • NHS Sotland. Multiple Sclerosis (Accessed 20/11/2020)

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.